First-line HIV treatment: evaluation of backbone choice and its budget impact
OBJECTIVE: The gradual increase of persons living with HIV, mainly due to the reduced mortality achieved with effective antiretroviral therapies, calls for increased rationality and awareness in health resources consumption also during the early illness phases. Aim of this work is the estimation of...
Main Authors: | Orietta Zaniolo, Massimiliano Povero, Paolo Bonfanti, Marco Borderi, Massimo Medaglia |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd Medical Publishers
2013-03-01
|
Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
Subjects: | |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/643 |
Similar Items
-
Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
by: Sharlene Ho, et al.
Published: (2020-05-01) -
The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection
by: A V Kravchenko, et al.
Published: (2014-11-01) -
Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa
by: Malewe Kolou, et al.
Published: (2021-07-01) -
Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings
by: Sasisopin Kiertiburanakul, et al.
Published: (2017-05-01) -
Tenofovir-induced quadriparesis
by: Ashalatha Muppur, et al.
Published: (2020-01-01)